We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Chronic HCV Increases Risk for Renal Cancer

By LabMedica International staff writers
Posted on 19 Jul 2010
An enzyme-linked immunoassay (ELISA) and a molecular assay for ribonucleic acid (RNA) were used to test a large cohort for a specific viral infection. More...


The cohort was tested for the presence of antibodies to Hepatitis C virus (HCV) and their infectivity by the molecular test to establish their risk for renal cell carcinoma (RCC).

The 67,063 participants were tested for HCV between 1997 and 2006, and followed to monitor development of RCC until April 2008 and about 5% were positive for the virus. RCC developed in 17 of the 3,057 (0.6%) who were HCV positive and in only 0.3% of 64,006 HCV negative participants. Among the HCV-positive RCC patients, the HCV RNA viral levels and genotypes, and liver histology were recorded.

The RCC cases in HCV positive patients included eight clear cell cancers, six papillary cancers, two mixed clear cell/papillary, and one undifferentiated neoplasm.

Among participants diagnosed with RCC, HCV positive patients were of a significantly younger average age than HCV negative patients were. Men were 2.4 times more likely to develop the malignancy than women were, and Afro-Americans had about a 40% higher risk than any other racial or ethnic group.

Chronic hepatitis C is primarily a disease of the liver, but it can also contribute to problems elsewhere in the body. Stuart C. Gordon, M.D., from Henry Ford Hospital, (Detroit, MI, USA) said, "These results add to growing literature that shows that the hepatitis C virus causes disease that extends beyond the liver, and in fact most of our HCV-infected kidney cancer patients had only minimal liver damage". The results were published in the April 2010 issue of Cancer Epidemiology Biomarkers and Prevention.

Related Links:

Henry Ford Hospital



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.